Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGYP
  • CUSIP: 87163930
  • Web:
  • Market Cap: $942.54 million
  • Outstanding Shares: 224,949,000
Average Prices:
  • 50 Day Moving Avg: $4.33
  • 200 Day Moving Avg: $4.84
  • 52 Week Range: $3.34 - $7.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.93
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $97,999.00
  • Price / Sales: 9,617.82
  • Book Value: $0.46 per share
  • Price / Book: 9.11
  • EBIDTA: ($180,110,000.00)
  • Return on Equity: -404.54%
  • Return on Assets: -158.66%
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 3.75%
  • Quick Ratio: 3.53%
  • Average Volume: 4.63 million shs.
  • Beta: 1053.07
  • Short Ratio: 11.15
Frequently Asked Questions for Synergy Pharmaceuticals (NASDAQ:SGYP)

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.07. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. View Synergy Pharmaceuticals' Earnings History.

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued twelve-month target prices for Synergy Pharmaceuticals' shares. Their predictions range from $3.70 to $18.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $11.13 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.

What are analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (7/18/2017)
  • 2. HC Wainwright analysts commented, "We remain confident that Synergy should secure this key extension to the Trulance™ label in early 2018, and thereby should be able to compete on an equal footing across the board with its closest comparator, Linzess® (linaclotide), from Allergan plc (AGN; not rated) and Ironwood Pharmaceuticals (IRWD; not rated). We continue to anticipate that Trulance™ should be able to achieve a market-leading position in treatment of both chronic idiopathic constipation (CIC) and IBS-C in the coming years." (6/12/2017)
  • 3. Cantor Fitzgerald analysts commented, "GC-C expertise should create new drugs and opportunities. SGYP’s pipeline leverages the company’s knowledge in modulating the effects of guanylate cyclase type C (GC-C) receptors to treat GI disorders. Lead drug candidates plecanatide and dolcanatide are designed to mimic the effects of the endogenous peptide hormone uroguanylin to restore normal GI function. We believe the strategy could lower the risk profile of the drug development programs. Trulance could be just what the Dr. ordered. Gastroenterologists we speak with acknowledge the relative effectiveness of CIC drugs but believe there is room for improvement particularly as it relates to tolerability. Amitiza and Linzess side effects may limit their usefulness and it would appear that Trulance produces a narrower range of them. With an sNDA recently filed for the IBS-C indication, SGYP could be in a position to create a new commercial opportunity in early 2018." (6/1/2017)
  • 4. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)
  • 5. Guggenheim analysts commented, "After the close, SGYP reported 4Q16 financial results and provided a business update. There was not much new in terms of the update though SGYP reiterated the launch timing for Trulance, which it expects later this month (March). We continue to believe Trulance will see strong uptake among patients and physicians given its improved tolerability and dosing profile relative to incumbent brands and benefit from the overall category growth of the chronic constipation market. We remain positive on SGYP's hybrid commercialization strategy which incorporates company-hired managers and reps from a contract sales organization. With the financing overhang gone, we believe shares are poised to appreciate as we begin to see paid scripts ramp which could be several months into the launch. Reiterate Outperform." (3/2/2017)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 60,743,279 shares, an increase of 1.6% from the June 30th total of 61,710,506 shares. Based on an average trading volume of 2,725,840 shares, the days-to-cover ratio is presently 22.3 days. Approximately 27.1% of the company's stock are sold short.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Gary G. Gemignani, Chief Financial Officer, Executive Vice President
  • Marino Garcia, Executive Vice President, Chief Strategy Officer
  • Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
  • Troy Hamilton, Executive Vice President, Chief Commercial Officer
  • Bernard F. Denoyer CPA, Senior Vice President, Finance, Secretary
  • Melvin K. Spigelman M.D., Lead Independent Director
  • Thomas H. Adams Jr. Ph.D., Independent Director
  • John P. Brancaccio CPA, Independent Director
  • Timothy S. Callahan, Independent Director

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Trellus Management Company LLC (0.15%), Clear Harbor Asset Management LLC (0.13%), Nisa Investment Advisors LLC (0.13%), Cheyne Capital Management UK LLP (0.06%), Carl Domino Inc (0.04%) and America First Investment Advisors LLC (0.03%). Company insiders that own Synergy Pharmaceuticals stock include Alan Joslyn, Bernard Denoyer, Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan. Company insiders that have sold Synergy Pharmaceuticals stock in the last year include John P Brancaccio and Paulson & Co Inc. View Insider Buying and Selling for Synergy Pharmaceuticals.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC, Nisa Investment Advisors LLC, Clear Harbor Asset Management LLC and Janney Montgomery Scott LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $4.19.

MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Synergy Pharmaceuticals (NASDAQ:SGYP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $11.13 (165.71% upside)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$9.00LowView Rating Details
7/10/2017Canaccord GenuityReiterated RatingBuy$13.00LowView Rating Details
6/28/2017Citigroup Inc.Reiterated RatingSell$3.70LowView Rating Details
6/27/2017BTIG ResearchReiterated RatingBuy$11.00HighView Rating Details
6/14/2017Rodman & RenshawReiterated RatingBuy$18.00MediumView Rating Details
6/12/2017HC WainwrightReiterated RatingBuy$18.00LowView Rating Details
6/9/2017Cantor FitzgeraldReiterated RatingOverweight$11.00LowView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Earnings History by Quarter for Synergy Pharmaceuticals (NASDAQ SGYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.23)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
2017 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 67.42%
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.00View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.68View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Synergy Pharmaceuticals (NASDAQ:SGYP)
Latest Headlines for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateHeadline logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 25, 2017 - July 26 at 7:20 AM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 24, 2017 - July 25 at 6:39 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Expected to Announce Quarterly Sales of $2.62 Million - July 22 at 8:00 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Expected to Post Earnings of -$0.22 Per Share - July 20 at 10:18 PM logoOppenheimer Holdings, Inc. Reaffirms Outperform Rating for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - July 18 at 12:36 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Rating Lowered to Sell at Zacks Investment Research - July 18 at 9:28 AM logoQ3 2017 EPS Estimates for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Lowered by Analyst - July 17 at 8:11 AM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : July 14, 2017 - July 15 at 8:32 AM logoWhat To Expect Ahead of Synergy Pharmaceuticals Inc (SGYP) 2Q Earnings; Oppenheimer’s Take - July 14 at 8:22 AM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Short Interest Up 5.3% in June - July 14 at 7:10 AM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Raised to "Hold" at Zacks Investment Research - July 12 at 5:28 PM logoSynergy Pharmaceuticals Inc (SGYP) Trulance Poses Enticing Long-Term Uptake - July 11 at 7:35 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Earns Buy Rating from Canaccord Genuity - July 10 at 9:02 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Receives Consensus Rating of "Hold" from Analysts - July 10 at 8:30 PM logoSynergy Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:SGYP) - July 7 at 8:13 AM logoSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Earns "Sell" Rating from Citigroup Inc. - July 2 at 1:20 PM logoSynergy Pharmaceuticals, Inc. (SGYP) Expected to Post Quarterly Sales of $2.82 Million - June 28 at 10:34 AM logoSynergy Pharmaceuticals Inc’s (SGYP) CIC Drug Set To Stay In Spotlight; BTIG Weighs In - June 27 at 8:18 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Rating Increased to Hold at BidaskClub - June 23 at 5:54 PM logoETFs with exposure to Synergy Pharmaceuticals, Inc. : June 15, 2017 - June 15 at 4:44 PM logoSynergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : June 14, 2017 - June 15 at 12:30 AM logoSynergy Pharmaceuticals' (SGYP) Buy Rating Reaffirmed at Rodman & Renshaw - June 14 at 9:44 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Given Average Rating of "Hold" by Brokerages - June 13 at 8:34 PM logoSynergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SGYP-US : June 13, 2017 - June 13 at 9:56 AM logoRodman & Renshaw Roots for Synergy Pharmaceuticals Inc. (SGYP) Ahead of Promising Commercial Trajectory for Trulance - June 13 at 9:56 AM logoReviewing Sucampo Pharmaceuticals (SCMP) & Synergy Pharmaceuticals (SGYP) - June 13 at 7:44 AM logoSynergy Pharmaceuticals, Inc. (SGYP) Stock Rating Reaffirmed by HC Wainwright - June 12 at 9:02 AM logoSynergy Pharmaceuticals Inc (SGYP) Sees Significant Growth in Short Interest - June 11 at 7:20 AM logoCantor Fitzgerald Reiterates Overweight Rating for Synergy Pharmaceuticals Inc (SGYP) - June 9 at 6:58 PM logoSynergy Pharma (SGYP) Anounces FDA Acceptance of sNDA for TRULANCE for IBS-C - June 8 at 2:25 AM logoSynergy Pharma (SGYP) Anounces FDA Acceptance of sNDA for TRULANCE for IBS-C - - June 8 at 2:25 AM logoSynergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C) - June 8 at 2:25 AM logoSynergy Pharmaceuticals: Oh Frabjous Day! - Seeking Alpha - June 6 at 10:26 PM logoToday's Research Reports on Stocks to Watch: Synergy Pharmaceuticals and Bioscrip Inc. - June 5 at 8:49 AM logoMid-Day Market Update: Crude Oil Down 2%; Synergy Pharma Shares Spike Higher - Benzinga - June 3 at 12:17 AM logoWhy Synergy Pharmaceuticals Shares Are Popping 16.7% Today - June 2 at 2:26 PM logoSynergy Pharmaceuticals Inc (SGYP) Expected to Announce Quarterly Sales of $2.82 Million - June 2 at 1:14 PM logoThoughts On Synergy Pharma's Valuation As Cantor Initiates At Overweight - June 2 at 10:21 AM logoMid-Morning Market Update: Markets Edge Hogher; Lululemon Beats Q1 Estimates - June 2 at 10:21 AM logoSynergy Pharmaceuticals Inc (SGYP) Now Covered by Analysts at Cantor Fitzgerald - June 1 at 10:34 PM logo Analysts Expect Synergy Pharmaceuticals Inc (SGYP) to Post -$0.22 Earnings Per Share - May 31 at 2:26 PM logoSynergy Pharmaceuticals' (SGYP) Buy Rating Reaffirmed at BTIG Research - May 31 at 9:56 AM logoSynergy Pharmaceuticals Inc (SGYP) Director John P. Brancaccio Buys 6,500 Shares - May 30 at 10:26 AM logoGary S. Jacob Buys 5,680 Shares of Synergy Pharmaceuticals Inc (SGYP) Stock - May 30 at 10:26 AM logoSynergy Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference - May 30 at 9:14 AM logoSynergy Pharmaceuticals Inc (SGYP) Given "Buy" Rating at Rodman & Renshaw - May 27 at 11:16 PM logoSynergy Pharmaceuticals Inc (SGYP) Sees Large Drop in Short Interest - May 26 at 7:10 AM logoSynergy Pharmaceuticals Inc (SGYP) Downgraded by ValuEngine to Sell - May 23 at 3:08 PM logoTechnical Reports on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma - May 22 at 9:00 AM logoSynergy Pharmaceuticals Inc (SGYP) Rating Reiterated by Canaccord Genuity - May 20 at 12:46 AM



Synergy Pharmaceuticals (SGYP) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff